Could Anaptysbio Inc (NASDAQ:ANAB) See a Reversal After More Sellers Came In?

June 18, 2018 - By Peter Erickson

The stock of Anaptysbio Inc (NASDAQ:ANAB) registered an increase of 3.2% in short interest. ANAB’s total short interest was 2.60 million shares in June as published by FINRA. Its up 3.2% from 2.52M shares, reported previously. With 264,700 shares average volume, it will take short sellers 10 days to cover their ANAB’s short positions. The short interest to Anaptysbio Inc’s float is 21.69%.

The stock increased 0.45% or $0.34 during the last trading session, reaching $75.25. About 458,469 shares traded or 11.90% up from the average. AnaptysBio, Inc. (NASDAQ:ANAB) has risen 191.76% since June 18, 2017 and is uptrending. It has outperformed by 179.19% the S&P500.

AnaptysBio, Inc., a clinical stage biotechnology company, engages in developing antibody product candidates focused on unmet medical needs in inflammation. The company has market cap of $1.77 billion. The companyÂ’s proprietary anti-inflammatory pipeline includes ANB020, an anti-interleukin-33 antibody for the treatment of moderate-to-severe adult atopic dermatitis, severe adult peanut allergy, and severe adult eosinophilic asthma; ANB019, an anti-interleukin-36R antibody for the treatment of rare inflammatory diseases, including generalized pustular psoriasis and palmo-plantar pustular psoriasis; and a portfolio of checkpoint receptor agonist antibodies for the treatment of certain autoimmune diseases. It currently has negative earnings. It also has an immuno-oncology partnership with TESARO, Inc. and TESARO Development, Inc. to develop and commercialize an anti-PD-1 antagonist antibody and an anti-TIM-3 antagonist antibody (TSR-022), which are under clinical development; and an inflammation partnership with Celgene Corporation to develop an anti-PD-1 checkpoint agonist antibody (CC-90006) that is in clinical stage.

More recent AnaptysBio, Inc. (NASDAQ:ANAB) news were published by: Streetinsider.com which released: “Anaptysbio (ANAB) Presents Updated ANB020 and ANB019 Clinical Data at EAACI” on May 29, 2018. Also Seekingalpha.com published the news titled: “Tracking Ole Andreas Halvorsen’s Viking Global Portfolio – Q1 2018 Update” on May 27, 2018. Nasdaq.com‘s news article titled: “AnaptysBio Presents Updated ANB020 and ANB019 Clinical Data at the 2018 EAACI Congress” with publication date: May 29, 2018 was also an interesting one.

AnaptysBio, Inc. (NASDAQ:ANAB) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: